Sibutramine
- Generic Name
- Sibutramine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H26ClN
- CAS Number
- 106650-56-0
- Unique Ingredient Identifier
- WV5EC51866
- Background
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October ...
- Indication
For the treatment of obesity.
- Associated Conditions
- Obesity
- Associated Therapies
- -
A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2008-09-15
- Lead Sponsor
- Nastech Pharmaceutical Company, Inc.
- Target Recruit Count
- 551
- Registration Number
- NCT00537420
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Salt Lake City, Utah, United States
Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS
- Conditions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2007-04-20
- Lead Sponsor
- Hippocration General Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT00463112
- Locations
- 🇬🇷
Hippocratio General Hospital, Thessaloniki, Greece
Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2011-03-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 181
- Registration Number
- NCT00433641
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 258
- Registration Number
- NCT00402077
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder
- Conditions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2007-08-31
- Lead Sponsor
- Abbott
- Target Recruit Count
- 304
- Registration Number
- NCT00402584
Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity
- Conditions
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2010-01-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 72
- Registration Number
- NCT00330525
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.
- Conditions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2007-08-31
- Lead Sponsor
- Abbott
- Target Recruit Count
- 498
- Registration Number
- NCT00261911
Adolescent Weight Management Study
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2015-04-17
- Target Recruit Count
- 120
- Registration Number
- NCT00212173
A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2009-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 282
- Registration Number
- NCT00134199
- Locations
- 🇺🇸
Pfizer Investigational Site, Tacoma, Washington, United States
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
- Conditions
- First Posted Date
- 2002-08-23
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 130
- Registration Number
- NCT00044187
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.